NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease that occurs in the setting of insulin resistance and increased adiposity. It has rapidly evolved into the most common liver disease seen in the pediatric population and is a management challenge for general pediatric practitioners, subspecialists, and for health systems. In this guideline, the expert committee on NAFLD reviewed and summarized the available literature, formulating recommendations to guide screening and clinical care of children with NAFLD.

Key Words: children, nonalcoholic fatty liver disease, recommendations, treatment

What Is Known
- Nonalcoholic fatty liver disease is a highly prevalent liver disease in children.
- Guidance is needed for clinical care decisions for pediatric nonalcoholic fatty liver disease.

What Is New
- The following recommendations are based on a formal review and analysis of the recently published world literature (PubMed and EMBASE search through May 2015), guidelines from other societies when applicable, and the experience of the expert committee.
- Recommendations for clinical practice, including screening, diagnosis, treatment, and public health considerations are covered in this pediatric guideline.

diagnosis of pediatric NAFLD were published in 2012 (3); however, it did not include screening, treatment, and public health implications. The North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and grants DK096157, DK61731, and DK107243 (M.B.V.) and DK088925, DK088831, and DK61734 (J.B.S). The content is solely the responsibility of the authors and does not necessarily represent the official views of NASPGHAN or the AAP. This project was endorsed by the American Academy of Pediatrics. M.B.V. has research funding from Resonance Health Inc, serves on a DMC for Aegerion, and as a consultant for Shire, Immuron, Intercept, and Target Pharmasolutions. S.R.D. serves on a DMC for Novo Nordisk and consults for Sanofi. R.K. has research funding from Raptor. The remaining authors report no conflicts of interest.

Copyright © 2016 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

DOI: 10.1097/MPG.0000000000001482
Gastroenterology, Hepatology and Nutrition (NASPGHAN) commissioned the Expert Committee on NAFLD to address this gap. The committee included specialists in general pediatrics, hepatology, gastroenterology, nutrition, cardiology, endocrinology, and pediatric obesity management.

The following recommendations are based on a formal review and analysis of the recently published literature (PubMed and EMBASE search through May 2015), guidelines from other societies when applicable, and the experience of the expert committee. These guidelines are intended for pediatricians, allied health professionals caring for children, pediatric gastroenterologists, hepatologists, endocrinologists, and preventive cardiologists. They suggest preferred evidence-based approaches for the clinical care of children related to NAFLD but remain flexible and adjustable for individual patients and circumstances. In areas in which insufficient evidence existed, the committee drew on the collective experience of the members to provide guidance.

The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system was used to classify the quality of evidence and strength of recommendations (Table 1). The strength of recommendation in the GRADE system is classified as strong or weak. The quality of evidence is characterized as high, moderate, or low quality. The GRADE system assesses the quality of evidence available. Specifically, it evaluates the methodological limitations of studies, whether the results of different studies are consistent or generalizable, and whether treatment approaches have been found to be effective (clinicalevidence.bmj.com). In this guideline, the term “children” includes 0 to 18 years.

### Table 1. Grading of recommendations, assessment, development and evaluation

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Strength of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factors influencing the strength of the recommendation included the quality of the evidence, presumed patient-reported outcomes and cost variability in preferences and values, or more uncertainty. Recommendation is made with less certainty, higher cost, or resource consumption</td>
<td>Weak [2]</td>
</tr>
<tr>
<td>Further research is unlikely to change confidence in the estimate of the clinical effect</td>
<td>Low [C]</td>
</tr>
<tr>
<td>Further research is likely to change confidence in the estimate of the clinical effect</td>
<td>Moderate [B]</td>
</tr>
<tr>
<td>Further research may change confidence in the estimate of the clinical effect</td>
<td>High [A]</td>
</tr>
</tbody>
</table>

### Table 2. Nonalcoholic fatty liver disease definitions and phenotypes

<table>
<thead>
<tr>
<th>Phenotypes</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAFLD</td>
<td>Inclusive term referring to the full spectrum of disease</td>
</tr>
<tr>
<td>NAFL</td>
<td>Steatosis without specific changes to suggest steatohepatitis, with or without fibrosis</td>
</tr>
<tr>
<td>Pediatric NASH</td>
<td>Hepatic steatosis with inflammation, with or without ballooning injury to hepatocytes and fibrosis</td>
</tr>
<tr>
<td>NAFLD with fibrosis</td>
<td>NAFL or NASH with perportal, portal, or sinusaloidal or bridging fibrosis</td>
</tr>
<tr>
<td>NAFLD with cirrhosis</td>
<td>Cirrhosis in the setting of NAFLD</td>
</tr>
</tbody>
</table>

Other terms such as “presumed NAFLD” (also “clinical NAFLD” or “suspected NAFLD”) are terms used in the literature with varying meanings. NAFL = nonalcoholic fatty liver; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis.

is associated with insulin resistance, central or generalized obesity, and dyslipidemia characterized by high triglyceride and low high-density lipoprotein (HDL) cholesterol levels.

Based on histology, NAFLD can be divided into nonalcoholic fatty liver (NAFL), which denotes bland steatosis, and nonalcoholic steatohepatitis (NASH), which is marked by steatosis and lobular inflammation and hepatocellular injury (Table 2). A further characterization is presence of fibrosis, which may indicate a more severe phenotype even in the absence of NASH. In some children, a unique periporal pathologic pattern of injury exists that has been termed “portal predominant NASH.” The significance of the periporal pattern for future clinical events is unknown and it is rarely seen in adults. In this document, the terms for NAFLD phenotypes are defined in Table 2.

### INCIDENCE AND PREVALENCE IN CHILDREN AND CLINICAL RISK FACTORS

At the time of the guideline development, there were no studies describing the incidence of NAFLD in children. Prevalence of NAFLD has been described both in the United States and internationally. The prevalence varies by method of detection, which may include screening by alanine aminotransferase (ALT), imaging for steatosis, or confirmation by liver biopsy. In North American studies, NAFLD prevalence ranges from 0.7% in young children ages 2 to 4 years (confirmed at autopsy), to 29% to 38% in obese children (by studies of ALT elevation and an autopsy study) (4–8). Moreover, the prevalence of NAFLD increased 2.7-fold from the late 1980s to the current era (2007–2010), and at a more rapid rate than childhood obesity, based on analysis of ALT elevation in serial National Health and Nutrition Examination Survey cohorts (7).

Prevalence varies by race/ethnicity. US studies have revealed a 4-fold increased risk of hepatic steatosis in Hispanic, compared...
with non-Hispanic adolescents (11–22 years old) (8). White and Asian children also have high prevalence, compared to African-American children (5). The prevalence also differs by sex, with most studies showing higher percentages in male compared to female children (5,9,10). Prevalence is higher in obese children compared with normal weight, although not all children with NAFLD are obese (5).

Several comorbidities have been associated with increased prevalence and/or severity of pediatric NAFLD, although the pathophysiology of these associations remains incompletely understood. Obstructive sleep apnea (OSA) was associated with the presence of NASH in 2 pediatric studies, independent of body mass index (BMI) and standard metabolic risk factors (11,12). It is not known whether OSA treatment ameliorates NASH. Among children newly diagnosed with type 2 diabetes mellitus (T2DM), elevated ALT is more frequent in Hispanic children compared to African American children (13). In addition, pediatric patients with panhypopituitarism appear to have increased risk of NAFLD, NASH, and even cirrhosis (14,15), similar to the increased prevalence (77%) and severity of NAFLD reported among adults with hypopituitarism (16). In summary, NAFLD is highly prevalent in children, with a greater risk in certain subpopulations; obese children; male children; Caucasian, Asian, and Hispanic children; and those with prediabetes, diabetes, OSA, and panhypopituitarism.

NATURAL HISTORY OF NONALCOHOLIC FATTY LIVER DISEASE IN CHILDREN

Two small retrospective studies reported results of repeat liver biopsies done for clinical indications in children receiving usual clinical care for NAFLD. The first study showed that fibrosis remained stable or resolved in 11 of 18 patients after an average of 28 months (17). Worsening fibrosis was reported in 4 out of 5 patients evaluated (18) in a retrospective study at a mean time frame of 41 months (18).

The natural history of pediatric NAFLD in the setting of lifestyle counseling was represented by the placebo arm of the TONIC trial, a 2-year randomized control trial designed to compare vitamin E, metformin, and placebo with liver biopsies at baseline and at 2-year follow-up (19). All 3 arms received nutrition and physical activity (lifestyle) advice. In the placebo cohort, 28% had resolution of NASH, 40% improved fibrosis, 40% improved steatosis, and 43% improved lobular inflammation. Progression of disease was seen in 25%. The mean change in ALT from baseline to week 96 was −35 (−57 to −14).

Longitudinal studies in adults demonstrate that patients with NAFLD have increased mortality compared with matched control populations (20). The increased mortality in adults is secondary to cardiovascular disease (CVD), cirrhosis, and hepatocellular carcinoma. In adults, fibrosis stage at baseline is the most predictive feature of future liver disease–related mortality (21). Pediatric NAFLD may be more severe compared to NAFLD identified in adulthood (22). Limited data suggest that children diagnosed with NAFLD have increased morbidity and mortality in adulthood (18).

Although limited, the pediatric data on the natural history of pediatric NAFLD support some conclusions. Fifteen percent of children with NAFLD have stage 3 fibrosis or higher at diagnosis (23) and disease in children appears to be more severe compared with adults (22). Given that pediatric disease is by definition early onset disease, it may represent an aggressive phenotype of the disease. Reports show that a few children have rapid progression to clinical events from NAFLD (death, transplant, diabetes, CVD).

Because such clinical events from pediatric NAFLD typically do not occur under the age of 21 years, studies determining clinical outcomes from pediatric NAFLD will require long-term follow-up into adulthood. Extrapolation from adult natural history studies may not be sufficient because today’s children are more likely to experience early onset of obesity, increased severity of obesity, and exposure in utero to maternal obesity and insulin resistance compared to children of prior decades (24).

SCREENING FOR NONALCOHOLIC FATTY LIVER DISEASE IN CHILDREN

Similar to other chronic liver diseases, NAFLD is often asymptomatic. Historically, NAFLD was frequently identified incidentally due to blood liver biochemistries or abdominal imaging, such as ultrasound or computed tomography (CT), ordered for other indications. Screening for NAFLD is appropriate because it can be detected before the onset of irreversible, end-stage liver disease. Identification of children with NAFLD is important because effective treatment is available (weight management through lifestyle improvements). Although more challenging to implement than prescribing a medication, lifestyle intervention can be effective at reversing NAFLD and even NASH, particularly if initiated early in the course of disease, before advanced fibrosis has developed.

Screening Tests

The currently recommended screening test, ALT, is an inexpensive, universally available blood test. ALT is minimally invasive and has an acceptable sensitivity. The assay is standardized between facilities; however, the reporting of normal values is not. Several studies have evaluated upper limits of normal in children. In the United States, sex-specific biologically based cutoffs have been determined from nationally representative data and have been validated in a fairly diverse cohort (25). These cutoffs are 22 mg/dL for girls and 26 mg/dL for boys. A Canadian study found the upper limit of normal for ALT to be 30 mg/dL in children 1 to 12 years of age, and 24 mg/dL in those between 13 and 19 years (26). For the diagnosis of NAFLD, the use of 2 times the sex-specific ALT (ALT ≥50 for boys and ≥44 for girls) in overweight and obese children age 10 years or older has a sensitivity of 88% and a specificity of 26% (27). NASH is more common in children with ALT ≥80 U/L compared to those with ALT <80 U/L (41% compared to 21%, respectively) (27).

Aspartate aminotransferase (AST) and gamma-glutamyl transferase (GGT) have not been independently tested as screening tools for NAFLD in children. In the context of elevated ALT, higher AST and higher GGT are associated with worse histology (27). Elevated AST or GGT in the context of normal ALT may, however, represent a condition other than NAFLD.

Imaging has also been used as a screening tool for NAFLD. Clinically available, routine ultrasonography performs poorly for the detection of steatosis in children because of its low sensitivity and specificity particularly in children who have lower degrees of steatosis (ie, involving <33% of hepatocytes) (28). In addition, ultrasound is inaccurate for quantification of steatosis in children with NAFLD. More precise ultrasound methodology has been developed (29); however, it is not widely available. The limitations of ALT and ultrasonography as screening tools for NAFLD can lead to inconsistencies, as patients with NAFLD can have an ALT <40 U/L in the context of ultrasonography that suggests the presence of steatosis and vice versa (27). Magnetic resonance imaging and spectroscopy (MRI and MRS) have been validated and shown to be
accurate for detection and quantification of hepatic steatosis in both adults and children (30,31). Clinical applications for MRI- and MRS-based measurement of hepatic steatosis are rapidly becoming available in pediatric centers. At this time, MR-based methods are not used widely for screening because of cost, lack of availability, and lack of validated cutoffs to determine NAFLD. This area is rapidly developing however, and some pediatric centers are already using MRI in clinical practice for the quantification of steatosis. Hepatic steatosis is sometimes also identified by CT scans, often performed for other clinical indications. Combined adult and pediatric data show that CT detects steatosis with a sensitivity of 46% to 72% and specificity 88% to 95% but is not typically performed as a screening test for NAFLD due to concerns about radiation exposure (32). When hepatic steatosis is incidentally identified by imaging studies performed for other clinical indications, further diagnostic work-up to determine the cause of steatosis is needed (see Diagnosis section).

The relative cost-effectiveness of these various screening modalities (ALT vs imaging) has not been studied. ALT is significantly less expensive compared to imaging modalities and therefore is preferred as the first-line screening test for NAFLD, despite its limitations.

**At-Risk Populations to Screen**

Overweight and obese children are at increased risk for NAFLD. Risk increases in the setting of cardiometabolic risk factors, including insulin resistance, prediabetes, diabetes, dyslipidemia, central adiposity, and in certain races and ethnicities as discussed above. Nonoverweight children with these cardiometabolic risk factors are also at risk for NAFLD. Genetic predisposition strongly affects the risk of NAFLD development and the overweight siblings and overweight parents of patients with NAFLD are at high risk of NAFLD (33). Siblings who are 10 years or older and have a BMI of ≥85th percentile are at high risk of NAFLD.

The optimal age to screen for NAFLD and the need for repeat screening are underestimated because of the lack of pediatric studies on incidence and natural history. A cross-sectional, autopsy-based study revealed a large prevalence difference between children ages 5 to 9 years and 10 to 15 years (5). A limitation of the present study was relatively few subjects within the mid-ages and the cross-sectional nature. Certain groups, such as Hispanics, may be at risk for earlier onset disease (34).

**Recommendations**

1. Selected children should be screened for NAFLD. Strength: 1, Evidence: B.

   Screening should be considered beginning between ages 9 and 11 years for all obese children (BMI ≥95th percentile) and for overweight children (BMI ≥85th and <94th percentile) with additional risk factors (central adiposity, insulin resistance, prediabetes or diabetes, dyslipidemia, sleep apnea, or family history of NAFLD/NASH). Strength: 1, Evidence: B.

   Early screening can be considered in younger patients with risk factors such as severe obesity, family history of NAFLD/NASH, or hypopituitarism. Strength: 2, Evidence: B.

   Consider screening of siblings and parents of children with NAFLD if they have known risk factors for NAFLD (obesity, Hispanic ethnicity, insulin resistance, prediabetes, diabetes, dyslipidemia). Strength: 2, Evidence: C.

2. Currently, the best screening test for NAFLD in children is ALT; however, it has substantial limitations. Strength: 1, Evidence: B.

   Interpretation of ALT should be based upon sex-specific upper limits of normal in children (22 U/L for girls and 26 U/L for boys) and not individual laboratory upper limits of normal. Strength: 1, Evidence: A.

   Persistently (>3 months) elevated ALT more than twice the upper limit of normal should be evaluated for NAFLD or other causes of chronic hepatitis. Strength: 1, Evidence: C.

   ALT of >80 U/L warrants increased clinical concern and timely evaluation, as the likelihood of significant liver disease is higher. Strength: 2, Evidence: C.

   Clinically available routine ultrasound is not recommended as a screening test for NAFLD in children due to inadequate sensitivity and specificity. Strength: 1, Evidence: B.

   When the initial screening test is normal, consider repeating ALT every 2 to 3 years if risk factors remain unchanged. Strength: 2, Evidence: C.

   Consider repeating screening sooner if clinical risk factors of NAFLD increase in number or severity. Examples include excessive weight gain or development of other medical problems that increase risk of NAFLD, such as type 2 diabetes or OSA. Strength: 2, Evidence: C.

**DIAGNOSIS OF PEDIATRIC NONALCOHOLIC FATTY LIVER DISEASE**

**Initial Evaluation**

NAFLD is a diagnosis of exclusion requiring presence of hepatic steatosis and exclusion of other causes of hepatic steatosis besides NAFLD (Table 3). Importantly, an obese or overweight child with chronically elevated liver enzymes should not be assumed to have NAFLD. Evaluating the cause of chronically elevated liver enzymes to establish a diagnosis is of NAFLD is important because it excludes other hepatic conditions, which may require specific treatments distinct from treatment of NAFLD. This cost-effectiveness of this approach is unknown but consequences of missing another liver disease requiring alternate treatment can be significant and serious. Until a test is developed specifically for NAFLD, it remains a diagnosis of exclusion.

The utility of noninvasive tools for the diagnosis of NAFLD has been assessed against the currently accepted clinical reference, which is hepatic histology. A review of the literature suggests that to date surrogate markers and scores developed to predict steatosis (eg, “NAFLD liver fat score,” “fatty liver index,” “hepatic steatosis index,” and the “pediatric prediction score”) are not accurate enough or sufficiently validated to be clinically useful (35). Other scores have also been shown to be inadequate in predicting the presence of steatosis (36) or remain to be validated (37).

Similar to the issues noted under screening, clinically available ultrasound technology is not accurate for the diagnosis of hepatic steatosis because of its low sensitivity and specificity (28,38). Although ultrasound is widely available and can exclude hepatic masses, cysts, or gallbladder pathology, a normal hepatic ultrasound cannot exclude the presence of NAFLD and therefore is not useful for the diagnosis or follow-up. CT although reasonably sensitive and specific for hepatic steatosis is not recommended for diagnosis due to radiation risk. When available, MRI and MRS are highly accurate for estimating steatosis (31,39,40). Further studies are needed in children to identify and validate cutoffs that have diagnostic accuracy for NAFLD.

**Assessment of Steatosis Severity**

It is currently not known whether the severity of steatosis in children with NAFLD predicts short- or long-term clinical outcomes. Noninvasive techniques for quantifying the degree of
TABLE 3. Differential diagnosis for pediatric hepatic steatosis

<table>
<thead>
<tr>
<th>Genetic/metabolic disorders</th>
<th>Medications</th>
<th>Dietary causes</th>
<th>Infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonalcoholic fatty liver disease</td>
<td>Amiodarone</td>
<td>Protein-energy malnutrition (Kwashiorkor)</td>
<td>Hepatitis C (genotype 3)</td>
</tr>
<tr>
<td>Fatty acid oxidation and mitochondrial disorders</td>
<td>Corticosteroids</td>
<td>Alcohol abuse</td>
<td></td>
</tr>
<tr>
<td>Citrin deficiency</td>
<td>Methotrexate</td>
<td>Rapid surgical weight loss</td>
<td></td>
</tr>
<tr>
<td>Wilson disease</td>
<td>Certain antipsychotics</td>
<td>Parenteral nutrition</td>
<td></td>
</tr>
<tr>
<td>Uncontrolled diabetes</td>
<td>Certain antidepressants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipodystrophies</td>
<td>HAART</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lysosomal acid lipase deficiency</td>
<td>Valproic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Familial combined hyperlipidemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abeta-/hypobetalipoproteinemia</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HAART = highly active antiretroviral therapy.

Diagnosing Steatohepatitis and Determining Nonalcoholic Steatohepatitis Severity

NASH is defined as the presence of hepatic steatosis with necroinflammation and hepatocellular injury with or without fibrosis (45). Identification of fibrosis in children with NASH and NAFLD is important because these phenotypes are expected to be more likely to progress to cirrhosis (46). Clinical parameters, such as the degree of obesity or the severity of metabolic dysregulation (47), and noninvasive markers of hepatocellular injury (eg, keratin 18) do not adequately distinguish patients with NAFL from those with NASH (48–55). ALT is not sensitive enough to predict with certainty the NAFLD phenotype or severity; however, NASH is more common in children with ALT ≥80 U/L compared to those with ALT <80 U/L (41% and 21%, respectively) (27).

Liver biopsy is the current standard to define the presence and severity of NAFLD, including the presence of NASH, and to eliminate alternative and/or concurrent diagnoses. Liver biopsy has inherent limitations for staging NAFLD because of the nonuniformity of disease throughout the liver in reference to the small sample of liver obtained. Adequate sample length (≥2 cm) and width decreases the risk of misclassification, but does not eliminate it. The NAS is a research tool for semiquantitatively rating features of the histology and its use was not intended to include the confirmation of a clinical diagnosis (56).

Liver biopsy is generally safe in children (57–60), including those who are overweight or obese (61), as it is associated with a low risk of complications. Children who are extremely obese (BMI ≥120% of the 95th percentile or BMI >35 kg/m², whichever is lower) may present special challenges due to difficulty assessing the position of the liver and increased depth of the subcutaneous adipose tissue layer, and may warrant referral to interventional radiology. The optimal timing of liver biopsy to confirm the diagnosis of NAFLD and to follow-up on its progression has not been established. Currently, clinical practice varies widely. Proceeding to liver biopsy should be a shared decision with the child’s caregiver made after discussion of the benefits and risks. Benefits of liver biopsy include identifying those with more severe or progressive disease so that they can pursue more intensive treatment if office-based lifestyle counseling fails. More intensive weight-management options may include referrals to multidisciplinary intensive lifestyle interventions or even surgical weight loss in a severely obese adolescent who meets additional clinical criteria. Importantly, liver biopsy differentiates other chronic liver diseases, such as autoimmune hepatitis, which can be challenging to exclude noninvasively.

Assessment of Fibrosis

Fibrosis in the setting of NAFLD is currently determined by liver histology and staged using a semiquantitative scale of 0 to 4 (56). Children with NAFLD may have fibrosis without NASH. In general, clinical signs and symptoms of advanced fibrosis and cirrhosis may include fatigue, splenomegaly, low platelets, AST/ALT ratio >1, spider angioma and palmar erythema. Decompensated cirrhosis can also present with abnormal bruising, variceal bleeding, ascites, jaundice, pruritus, and encephalopathy. Overt signs and symptoms of advanced fibrosis or cirrhosis are, however, uncommon in children with NAFLD and NASH. Limited data suggest that clinical markers, such as higher BMI and increased waist circumference, are associated with the presence of fibrosis in patients with NAFLD/NASH (62,63). In a predominantly adult population, the NAFLD fibrosis score predicts the presence of fibrosis with moderate accuracy (64). The Pediatric NAFLD fibrosis score is less accurate; however, these results remain to be validated (65). Limited data suggest that the combined Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis scores are accurate in estimating fibrosis in children with NAFLD; however, the Pediatric NAFLD Fibrosis Index alone and the Pediatric NAFLD fibrosis score are less accurate (65–67). The accuracy of currently marketed fibrosis biomarker tests in children, and markers such as AST to platelet ratio and hyaluronic acid (and their optimal cutoffs), remain to be determined (68–72). In a predominantly Hispanic cohort of children presenting to an outpatient gastroenterology clinic for suspected fatty liver disease, an ALT ≥80 was associated with advanced fibrosis (bridging or cirrhosis) with a sensitivity of 76% and specificity of 59% (27).

In terms of imaging modalities for the assessment of fibrosis, acoustic radiation force impact, transient elastography and magnetic resonance elastography have predominantly been assessed in adults and are becoming more widely available at many centers. The pediatric literature is, however, characterized by small sample size, and particularly small numbers of patients with clinically significant fibrosis (≥2). Transient elastography has been shown to have a performance of 0.79 to 1.0 for predicting clinically...
significant fibrosis (73–75). MRE detects clinically significant fibrosis with a receiver operating characteristic curve of 0.92 and is scanner and reader independent (76). These technologies would benefit from further validation studies to determine optimal cut-points and ability to longitudinally track fibrosis in children.

**Recommendations**

4. When evaluating a child suspected to have NAFLD, it is recommended to exclude alternative etiologies for elevated ALT and/or hepatic steatosis and investigate the presence of coexisting chronic liver diseases (Fig. 1). Strength: 1, Evidence: A.

5. Liver biopsy should be considered for the assessment of NAFLD in children who have increased risk of NASH and/or advanced fibrosis. Potential clinical signs of increased risk of fibrosis in children with NASH may include higher ALT (>80 U/L), splenomegaly, and AST/ALT >1. Known clinical risk factors for NASH and advanced fibrosis include panhypopituitarism and type 2 diabetes. Strength: 1, Evidence: B.

6. The use of ultrasound is not recommended for the determination or quantification of steatosis due to poor sensitivity and specificity. Ultrasound may be useful for assessing other causes of liver disease such as masses, gallbladder disease, changes associated with portal hypertension, and so on. Strength: 1, Evidence: B.

7. The use of CT is not recommended for determination or quantification of steatosis due to radiation risk. Strength: 1, Evidence: B.

**TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN CHILDREN**

In the review of treatment of pediatric NAFLD, 42 clinical trials performed in children with NAFLD were identified. Limitations of the studies included a lack of standardization in the diagnostic criteria used, nonrandomization or lack of adequate control groups, insufficient treatment (eg, lifestyle intervention of short duration or subtherapeutic medication dose), inconsistent or inadequately defined outcomes, and varying approaches to data analysis. Conducting treatment trials for NAFLD in children remains challenging because of the lack of validated noninvasive biomarkers and insufficient knowledge of the natural history of the disease. High-quality treatment studies require histologic assessment of liver outcomes or, at minimum, a quantitative noninvasive measurement of liver fat and/or fibrosis, and a biochemical measurement of liver inflammation (ALT). Substantial ALT decrease (if elevated at entry) or normalization may also be an acceptable surrogate in NAFLD treatment trials, particularly in early phase studies, but is less accurate than histology or imaging.

**Goals of Treatment**

The most commonly accepted goal of treatment is regression of NAFLD, defined as decrease in steatosis, inflammation, and/or fibrosis. A second accepted goal is resolution of NASH. The durability of these histologic changes in children is unknown. Decrease in ALT is commonly used as a surrogate marker of improvement in histology of NAFLD, because there is some evidence to support its use in pediatric clinical trials (19,77). Although an ALT at a single time-point has poor correlation to phenotype, a decrease in ALT of 10 U/L during 96 weeks is associated with 1.28 relative odds of improvement in histology and 1.37 relative odds of resolution of NASH (77). In studies of NAFLD detected in adulthood, presence of fibrosis was more predictive of clinical outcome compared presence of NASH (46,78). Both NAFL and NASH have been shown to progress in stage of fibrosis (79). Until natural history studies are completed in children, these data are the best information available and can help inform current practice.

Ultrasound is not able to reliably detect changes in steatosis and therefore does not have a role in assessing steatosis longitudinally. Likewise, CT and MRI/MRS modalities have not been adequately studied in children with NAFLD as surrogate markers for NAFLD or NASH improvement. Liver biopsy remains the clinical standard for determining improvement in liver histology after treatment, but frequency and timing of a follow-up biopsy must be weighed against the risks of the procedure.

An additional and overarching goal of treatment for patients with NAFLD is to decrease excess adiposity to improve dyslipidemia, insulin resistance, high blood pressure, and central adiposity, all of which are closely associated with NAFLD, and with T2DM and CVD risk. In children, the NAFLD comorbidities (diabetes, CVD, and hypertension) are important considerations of treatment to improve future clinical outcomes.

**Recommendations**

8. Pending the development of more accurate biomarkers to noninvasively assess improvement in NAFLD, sustained decrease in ALT from baseline may be used as a surrogate marker of response to treatment, particularly for durations of ≤1 year. Strength: 2, Evidence: C.

9. Assessment of change in fibrosis over time is reasonable as a treatment outcome in children over longer time periods (≥2 years) and currently requires a liver biopsy for staging. Strength: 2, Evidence: – C.

**Treatment of Pediatric Nonalcoholic Fatty Liver Disease With Lifestyle Changes**

At this time, dietary improvements and increasing physical activity (lifestyle modifications) are the primary treatment for pediatric NAFLD because of the strong association with excess weight gain and obesity. Seventeen lifestyle intervention studies were identified in the literature search, but these were heterogeneous in design, including varying duration (1 month to 1 year), entry criteria, outcome measures, and lifestyle approaches. Nonetheless, there were a number of nonrandomized, uncontrolled cohorts that together demonstrate a trend of improvement in noninvasive markers of NAFLD (ALT and steatosis) with combined lifestyle and exercise (80–96). Multidisciplinary clinics designed to treat obesity have also reported improved liver enzymes and histology in children with NAFLD (81,97,98). Multidisciplinary lifestyle approaches of moderate to high intensity (>25 contact
FIGURE 1. An algorithm proposed by the expert committee on NAFLD (ECON) group. Further research is likely to alter the algorithm. The steps are suggested courses of action and should be interpreted within the clinical scenario of individual patients. ALT = alanine aminotransferase; GI = gastrointestinal; NAFLD = nonalcoholic fatty liver disease; ULN = upper limit of normal.

Additional testing for chronic liver diseases to consider:

- **Screening labs**: Complete blood count (CBC) with differential, AST, bilirubin (total, conjugated), alkaline phosphatase, GGT, international normalized ratio (INR), albumin, total protein, hemoglobin A1c
- **Exclude infections**: (eg, hepatitis A IgM, hepatitis B surface antigen, hepatitis C antibody, other chronic viral infections)
- **Exclude endocrine disorders**: (thyroid-stimulating hormone [TSH], free thyroxine [T4])
- **Exclude autoimmune causes of ALT elevation**: (total IgA, total IgG and tissue transglutaminase antibody, antinuclear antibody, antismooth muscle antibody, anti–liver-kidney microsomal antibody)
- **Exclude genetic causes of ALT**: (ceruloplasmin and/or 24-hour urine copper, lysosomal acid lipase, alpha-1 antitrypsin phenotype)
- **Imaging**: Abdominal ultrasound to rule out anatomical abnormalities or assess features of portal hypertension, magnetic resonance imaging, or spectroscopy to measure hepatic fat
- **Liver biopsy**: (histology, copper measurement, stain for microvesicular fat, assess fibrosis)

Red flags for advanced liver disease—chronic fatigue, gastrointestinal (GI) bleeding, jaundice, splenomegaly, firm liver on examination, enlarged left lobe of the liver, low platelets, low white blood cell count, elevated direct bilirubin, elevated international normalized ratio (INR), long history of elevated liver enzymes (>2 years).
Treatments for pediatric NAFLD. NAFLD = nonalcoholic fatty liver disease.

FIGURE 2. Treatments for pediatric NAFLD. NAFLD = nonalcoholic fatty liver disease.

Recommendation

10. Lifestyle modifications to improve diet and increase physical activity are recommended as the first-line treatment for all children with NAFLD. Strength: 1, Evidence: B.

11. Avoidance of sugar-sweetened beverages is recommended as a strategy to decrease adiposity. Strength: 1, Evidence: A.

12. Increasing moderate to high-intensity physical activity and limiting screen time activities to <2 hours per day is recommended for all children including those with NAFLD. Strength: 1, Evidence: B.

Medications and Supplements

A number of medications and supplements have been considered for use in pediatric NAFLD. Multiple clinical trials or cohort studies have focused on metformin (19,103–106) or vitamin E (19,107–110) as potential treatments for NAFLD. Metformin and lifestyle counseling or vitamin E and lifestyle counseling were each tested against placebo and lifestyle counseling in a large, multicenter, 3-arm RCT; the TONIC trial (19). Sustained ALT reduction was the primary endpoint and change in histology the secondary endpoint in the present study, which included 173 children ages 8 to 17 years. Although the primary outcome of sustained reduction of ALT was not different between either drug or placebo, vitamin E treatment was associated with statistically significant improvements in histology, as shown by a lower NAS (via improvement in ballooning) and greater resolution of NASH. The latter was shown in a smaller subset of participants who had biopsy-confirmed NASH. Concerns about the safety of high dose vitamin E have been raised in adults, following meta-analyses of clinical trials, which have indicated an increased mortality with vitamin E, and increased adverse cardiovascular events and prostate cancer (111,112). Interestingly, other meta-analyses have not had similar results (113). Although no significantly greater risk of adverse events were noted in the children receiving high-dose vitamin E in the TONIC trial over a 2-year period, the long-term benefits and risks remain unknown.

Vitamin E, as a treatment for biopsy-confirmed NAFLD, has also been tested in a smaller RCT in combination with lifestyle counseling and vitamin C; the 2 antioxidants taken together were, however, not superior to lifestyle intervention alone (109). High rates of vitamin D insufficiency have been identified in pediatric NAFLD (114–116), but there are no trials in children evaluating vitamin D supplementation as a treatment for NAFLD. In a small study of ursodeoxycholic acid in children, diet alone compared to ursodeoxycholic acid plus diet or ursodeoxycholic acid without diet did not show any benefit of the drug (117). This concurs with adult data that do not support its use in NAFLD (118).

Both docosahexaenoic acid (DHA) and fish oil have been considered for treatment of NAFLD. A small RCT testing 6 month supplementation with either 250 or 500 mg DHA compared with placebo for pediatric NAFLD found no improvement in ALT (119). An adult study suggests that fish oil worsens NASH (120). Probiotics (Lactobacillus GG and VSL 3) have been tested in 2 small studies of short duration (2–4 months); however, both studies were limited by the use of sonographic outcome measures (121,122). ALT improved significantly in 1 study compared to placebo and this could represent an area for future research.

In summary, no medication or supplement has been shown to be of significant value for the management of NAFLD in children.

Recommendations

13. No currently available medications or supplements are recommended to treat NAFLD because none have been proven to benefit the majority of patients with NAFLD. Strength: 2, Evidence: C

Weight Loss Surgery as a Treatment for Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis in Children

Bariatric or weight loss surgery (WLS) can lead to clinically meaningful weight loss in severely obese adolescents (minimum
BMI ≥35 kg/m² with average BMI reductions of approximately 30% at 1 year postoperatively after both Roux-en-y gastric bypass and vertical sleeve gastrectomy in a large multicenter adolescent cohort (123). At 3 years after surgery, an average 28% weight reduction was maintained in the cohort. This reduction in BMI is typically associated with substantial improvement and even resolution of many obesity-related comorbid conditions, including dyslipidemia, high blood pressure, insulin resistance, diabetes, and sleep apnea at 1 to 2 years postoperatively (124,125). Because these conditions are often associated with the presence of NAFLD and because studies in adults undergoing bariatric surgery have suggested a high degree (up to 89%) of NASH resolution 1 to 2 years postoperatively (126), severe NASH has been proposed as a criterion for WLS in several published adolescent bariatric surgery guidelines (127).

There is paucity of data on the natural history of NAFLD and NASH in adolescents undergoing WLS. There are only 4 WLS outcome studies in this population that have included an assessment of NAFLD status at baseline (128–132), and among those only 1 included histological evaluation of NAFLD (131). Interestingly, in terms of outcome after WLS, only 1 study provided data on the progression of the liver disease. The present study did not include histological outcomes but instead followed the change in ALT and AST in 81 adolescents undergoing Roux-en-y gastric bypass over a 2-year period (132). Mean ALT and AST improved significantly at 1 and 2 years (mean decrease of approximately 50%); however, no data on ALT/AST change were provided for the adolescent group undergoing conventional care (controls); therefore, it is unknown whether this intervention was superior to lifestyle intervention. It should be noted that similar to adult cohorts, the proportion of patients with severe NASH among adolescents undergoing WLS tend to be low (130). It is unclear whether this is related to selection/referral bias or due to potential biological differences among the more severely obese. Therefore, the generalizability of the overall positive NAFLD outcomes reported among adults undergoing bariatric surgery to children with histologically advanced or fibrotic NASH is limited.

Recommendation

14. Bariatric surgery is not recommended as a specific therapy for NAFLD given lack of outcome data in adolescents. Bariatric surgery may be considered for selected adolescents with BMI ≥35 kg/m², who have noncirrhotic NAFLD and other serious comorbidities (eg, T2DM, severe sleep apnea, idiopathic intracranial hypertension) that are likely to improve with WLS. Strength: 1, Evidence: B.

CARDIOVASCULAR DISEASE RISK IN THE SETTING OF NONALCOHOLIC FATTY LIVER DISEASE IN CHILDREN

Longitudinal studies in adults demonstrate an independent increase in CVD associated with markers of NAFLD (133–136). This risk (ranging from 1.23 to 4.82 increase in odds of events or disease) appears to be independent of classical risk factors such as BMI, obesity, or other components of the metabolic syndrome (136). In several adult studies, CVD has been found to be the leading cause of mortality in patients with biopsy proven NAFLD (20,137). To date, there are no studies reporting the effect of NAFLD diagnosed in childhood on the risk of CVD in adulthood. Abundant evidence, however, demonstrates that CVD risk factors, and specifically dyslipidemia, are commonly associated with NAFLD in children (138,139). The most common pattern of dyslipidemia is high triglycerides and low HDL, typical of the insulin-resistant state. Studies evaluating surrogate markers of atherosclerosis and autopsy findings of atherosclerosis confirm that children with NAFLD frequently have early atherosclerosis (140–144).

There are no studies in the pediatric population using lipid-lowering drugs as a treatment of NAFLD. The effect of lipid-lowering medications on NAFLD histology is also unknown. In adults, statins are recommended as safe for treating dyslipidemia in the setting of NAFLD; however, they are not used as a treatment of NAFLD (2). A few studies in children have evaluated the response of plasma lipids to treatments of NAFLD. In a 2-year trial testing the effect of DHA supplementation versus placebo for treating NAFLD in children, triglycerides improved in the DHA group compared with placebo (145). In the TONIC trial, resolution of NASH was associated with improvement in LDL and non-HDL cholesterol but not with improvement in triglycerides (19,146). Finally a small pilot study of a low-fructose diet demonstrated improved levels of oxidized LDL, a marker of CVD risk in children with NAFLD (96).

Despite the lack of pediatric data specifically on NAFLD, there is evidence to support the approach to CVD risk reduction in children. The “Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report” delineates current practice recommendations for screening and treating children (147). At the time of this document, universal screening with a lipid panel is recommended for all children ages 9 to 11 years (17). For ages 2 to 8 years, a lipid panel is recommended if risk factors exist or if there is a family history of dyslipidemia or of CVD. Management algorithms are detailed in the Summary Report and are useful when evaluating dyslipidemia in children with NAFLD.

Children with NAFLD are at increased risk of hypertension compared with obese children without NAFLD, a risk that persists over time (23,139). Guidelines exist on monitoring and treating hypertension in overweight children that are applicable to children with NAFLD (148).

Recommendations

15. Children with NAFLD should be screened for dyslipidemia at diagnosis and periodically as indicated by current lipid guidelines for children. Strength: 1, Evidence: B.

16. It is recommended to monitor blood pressure in children with NAFLD. Strength: 1, Evidence: B.

PREDIABETES AND DIABETES IN THE SETTING OF NONALCOHOLIC FATTY LIVER DISEASE

Limited pediatric data exist on the prevalence of prediabetes or T2DM in subjects with NAFLD. A retrospective analysis of a pediatric cohort with T2DM revealed the prevalence of elevated serum aminotransferases to be 48%, with 60% of these elevations being 2 or more times above the upper limit of normal (149). Recent cross-sectional and longitudinal studies have described an association between NAFLD and glucose dysregulation (150). In a cohort of 677 children with biopsy-confirmed NAFLD, prediabetes and diabetes were associated with significantly higher odds of having NASH (odds ratio 1.8 and 2.6, respectively) (151). Assessment of a relatively large multiethnic cohort of obese adolescent males revealed that the prevalence of prediabetes and metabolic syndrome increases significantly with increases in hepatic fat content measured with MRI (152).

Studies also indicate that hepatic steatosis is related to metabolic parameters in the longitudinal setting. A cohort of 76 children with obesity showed that both glucose (fasting and 2-hour blood glucose and area under the curve 2-hour blood glucose) and insulin sensitivity (whole body insulin sensitivity index) indices at a
mean follow-up of 1.9 years are significantly correlated with baseline hepatic fat content (150). More importantly, during the follow-up, a significant improvement of β-cell function in subjects with low compared with high liver fat content occurred. These relevant correlations were further confirmed by the multiple, stepwise, linear regression analysis showing an independent relation between baseline hepatic fat and longitudinal metabolic parameter (2-hour blood glucose and whole body insulin sensitivity index) even after adjusting for confounding factors (age, sex, ethnicity, BMI z-score, change in BMI z-score, and duration of follow-up).

**Recommendation**

17. It is recommended to screen children with NAFLD for diabetes at diagnosis and annually (or sooner if clinical suspicion arises) using either a fasting serum glucose level or a glycosylated hemoglobin (HbA1c) level. A glucose tolerance test may be useful if the fasting glucose or HbA1c are in the prediabetic range (Table 4). Strength: 1, Evidence: A

**LONG-TERM CARE FOR CHILDREN WITH NONALCOHOLIC FATTY LIVER DISEASE**

**Clinical Care**

Clinical care and intensity of follow-up may depend on the severity of the disease (more advanced NASH vs NAFL), similar to other chronic liver diseases that occur in the same age range (autoimmune hepatitis, hepatitis B (HB), hepatitis C, and primary sclerosing cholangitis). The optimal frequency of follow-up or laboratory/biopsy reassessment has not been studied in children with NAFLD; however, more frequent visits are known to be beneficial for nutrition and physical activity counseling in overweight and obese children (97,153) and may contribute to success of NAFLD treatment as well (97,153), as shown in adults (154). A decrease in ALT is commonly used as a surrogate marker of improvement in histology of NAFLD, and there is some evidence to support its use in pediatric clinical trials (19,77). Importantly, in the individual patient, it does not always reliably correlate with improvement or worsening of disease. At this time, there are no noninvasive modalities adequately validated for detecting progression or regression of fibrosis in children. Therefore, at this time liver biopsy remains the best available method for assessing change in fibrosis in children with NAFLD.

**Recommendations**

18. It is recommended to follow children with NAFLD on a yearly basis at a minimum to monitor for progression of disease and provide treatment. Strength: 1, Evidence: C.

19. When providing lifestyle counseling, more frequent visits (more contact hours with program staff) are associated with better weight management outcomes in overweight and obese children and therefore may also benefit overweight children with NAFLD/NASH. Strength: 1, Evidence: B.

20. A repeat liver biopsy to assess progression of disease (particularly fibrosis) and to guide treatment is reasonable to consider 2 to 3 years after the first liver biopsy, especially in patients with new or ongoing risk factors, such as T2DM, NASH, or fibrosis at diagnosis. Strength: 2, Evidence: C.

**Exposures to Liver Toxins**

Adolescence is a time of increased participation in high-risk behaviors with concurrent opportunities for establishing better health habits. Although emerging epidemiologic evidence suggests that light to moderate drinking may have a favorable effect on NAFLD (155), underage alcohol consumption is not recommended. A threshold effect may occur, with heavy, episodic drinking (eg, “binge drinking”) in adults associated with an increased risk of fibrosis progression (156). Binge drinking is common amongst adolescents, with a potential negative effect in those affected by NAFLD. Prolonged cigarette smoking has been associated with advanced histologic severity of NAFLD in adults (157). A cross-sectional study of 355 American children revealed that secondhand smoke exposure was associated with an increased prevalence of ultrasonographic evidence of hepatic steatosis (158).

**Recommendations**

21. In addition to standard counseling of adolescents, healthcare providers should counsel adolescents regarding the potential effects of increased fibrosis progression with binge drinking. Strength: 1, Evidence: B.

22. Families of children with NAFLD should be counseled about risks of secondhand smoke exposure and adolescents with NAFLD should be counseled against smoking and use of electronic nicotine delivery devices. Strength: 1, Evidence: B.

**Prevention of Hepatitis A and B**

Children with chronic liver disease are at increased risk of morbidity and mortality if infected with hepatitis A or B, vaccine-preventable diseases. Although data specific to pediatric NAFLD are lacking, children with other chronic liver diseases seroconvert after 2 doses of hepatitis A vaccination (159,160). The Red Book currently recommends that all children with liver diseases should receive hepatitis A vaccine (161). Universal vaccination for HB as infants began in 1991, so the vast majority of children and adolescents with NAFLD have been vaccinated. Children vaccinated for HB as infants frequently have low levels of HB surface antibody (anti-HBs) (162). Despite this, they usually have persistence of immune memory as demonstrated by Spradling et al (163) in which of those with no detectable HB

---

**TABLE 4. Definitions of prediabetes and diabetes by the American Diabetes Association**

<table>
<thead>
<tr>
<th></th>
<th>HgbA1c</th>
<th>Fasting glucose</th>
<th>2-hour OGTT</th>
<th>Random glucose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prediabetes</td>
<td>5.7%–6.4%</td>
<td>100–125 mg/dL (5.6–6.9 mmol/L)</td>
<td>140–199 mg/dL (7.8–11.0 mmol/L)</td>
<td>≥200 mg/dL (11.1 mmol/L)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>≥6.5%</td>
<td>≥126 mg/dL (7.0 mmol/L)</td>
<td>≥200 mg/dL (11.1 mmol/L)</td>
<td>≥200 mg/dL (11.1 mmol/L)</td>
</tr>
</tbody>
</table>

1 DCCT = diabetes control and complications trial; OGTT = oral glucose tolerance test.
2 Laboratory using method that is NGSP certified and standardized to the DCCT assay.
3 Fasting is defined as no caloric intake for at least 8 hours.
4 Test should be performed as described by the World Health Organization.
TABLE 5. Summary of recommendations

1. Selected children should be screened for NAFLD. Strength: 1, Evidence: A
   a. Screening should be considered beginning between ages 9 and 11 years for all obese children (BMI >95th percentile) and for overweight children (BMI >85th and <94th percentile) with additional risk factors (central adiposity, insulin resistance, prediabetes or diabetes, dyslipidemia, sleep apnea, or family history of NAFLD/NASH). Strength: 1, Evidence: B
   b. Earlier screening can be considered in younger patients with risk factors such as severe obesity, family history of NAFLD/NASH, or hypopituitarism. Strength: 2, Evidence: B
   c. Consider screening of siblings and parents of children with NAFLD if they have known risk factors for NAFLD (obesity, Hispanic ethnicity, insulin resistance, prediabetes, diabetes, dyslipidemia). Strength: 2, Evidence: C

2. Currently, the best screening test for NAFLD in children is ALT; however, it has substantial limitations. Strength: 1, Evidence: B
   a. Interpretation of ALT should be based upon sex-specific upper limits of normal in children (22 U/L for girls and 26 U/L for boys) and not individual laboratory upper limits of normal. Strength – 1, Evidence – A
   b. Persistently (>3 months) elevated ALT more than twice the upper limit of normal should be evaluated for NAFLD or other causes of chronic hepatitis. Strength: 1, Evidence: C
   c. ALT of >80 U/L warrants increased clinical concern and timely evaluation, as the likelihood of significant liver disease is higher. Strength: 2, Evidence: C
   d. Clinically available routine ultrasound is not recommended as a screening test for NAFLD in children due to inadequate sensitivity and specificity. Strength: 1, Evidence: B

3. Follow-up screening for NAFLD is recommended. Strength: 2, Evidence: C
   a. When the initial screening test is normal, consider repeating ALT every 2 to 3 years if risk factors remain unchanged. Strength: 2, Evidence: C
   b. Consider repeating screening sooner if clinical risk factors of NAFLD increase in number or severity. Examples include excessive weight gain or development of other medical problems that increase risk of NAFLD, such as type 2 diabetes or obstructive sleep apnea. Strength: 2, Evidence: C

4. When evaluating a child suspected to have NAFLD, it is recommended to exclude alternative etiologies for elevated ALT and/or hepatic steatosis and investigate the presence of coexisting chronic liver diseases (Fig. 1). Strength: 1, Evidence: A

5. Liver biopsy should be considered for the assessment of NAFLD in children who have increased risk of NASH and/or advanced fibrosis. Potential clinical signs of increased risk of fibrosis in children with NASH may include higher ALT (>80 U/L), splenomegaly, and AST/ALT >1. Known clinical risk factors for NASH and advanced fibrosis include panhypopituitarism and type 2 diabetes. Strength: 1, Evidence: B

6. The use of ultrasound is not recommended for the determination or quantification of steatosis due to poor sensitivity and specificity. Ultrasound may be useful for assessing other causes of liver disease such as masses, gallbladder disease, changes associated with portal hypertension, and so on. Strength: 1, Evidence: B

7. The use of CT is not recommended for determination or quantification of steatosis due to radiation risk. Strength: 1, Evidence: B

8. Pending the development of more accurate biomarkers to noninvasively assess improvement in NAFLD, sustained decrease in ALT from baseline may be used as a surrogate marker of response to treatment, particularly for durations of ≤1 year. Strength: 2, Evidence: C

9. Assessment of change in fibrosis over time is reasonable as a treatment outcome in children over longer time periods (≥2 years) and currently requires a liver biopsy for assessment. Strength: 2, Evidence: C

10. Lifestyle modifications to improve diet and increase physical activity are recommended as the first-line treatment for all children with NAFLD. Strength: 1, Evidence: B

11. Avoidance of sugar-sweetened beverages is recommended as a strategy to decrease adiposity. Strength: 1, Evidence: A

12. Increasing moderate- to high-intensity physical activity and limiting screen time activities to <2 hours per day is recommended for all children including those with NAFLD. Strength: 1, Evidence: B

13. No currently available medications or supplements are recommended to treat NAFLD because none have been proven to benefit the majority of patients with NAFLD. Strength: 2, Evidence: C

14. Bariatric surgery is not recommended as a specific therapy for NAFLD given lack of outcome data in adolescents. Bariatric surgery may be considered for selected adolescents with BMI ≥35 kg/m², who have noncirrhotic NAFLD and other serious comorbidities (eg, T2DM, severe sleep apnea, idiopathic intracranial hypertension) that are likely to improve with WLS. Strength: 1, Evidence: B

15. Children with NAFLD should be screened for dyslipidemia at diagnosis and periodically as indicated by current lipid guidelines for children. Strength: 1, Evidence: B

16. It is recommended to monitor blood pressure in children with NAFLD. Strength: 1, Evidence: B

17. It is recommended to screen children with NAFLD for diabetes at diagnosis and annually (or sooner if clinical suspicion arises) using either a fasting serum glucose level or an HbA1c level. A glucose tolerance test may be useful if the fasting glucose or HbA1c are in the prediabetic range (Table 3). Strength: 1, Evidence: A

18. It is recommended to follow children with NAFLD on a yearly basis at a minimum to monitor for progression of disease and provide treatment. Strength: 1, Evidence: C

19. When providing lifestyle counseling, more frequent visits (more contact hours with program staff) are associated with better weight management outcomes in overweight and obese children and therefore may also benefit overweight children with NAFLD/NASH. Strength: 1, Evidence B

20. A repeat liver biopsy to assess progression of disease (particularly fibrosis) and to guide treatment is reasonable to consider 2 to 3 years after the first liver biopsy, especially in patients with new or ongoing risk factors, such as type 2 diabetes mellitus, NASH, or fibrosis at diagnosis. Strength: 2, Evidence: C

21. In addition to standard counseling of adolescents, healthcare providers should counsel adolescents regarding the potential effects of increased fibrosis progression with binge drinking. Strength: 1, Evidence: B

22. Families of children with NAFLD should be counseled about risks of secondhand smoke exposure and adolescents with NAFLD should be counseled against smoking and use of electronic nicotine delivery devices. Strength: 1, Evidence: B

23. Children with NAFLD should be vaccinated routinely against hepatitis A. Strength: 1, Evidence: B

24. Children with NAFLD should have prior receipt of hepatitis B vaccine verified and be immunized if no prior vaccination was received. Strength: 1, Evidence: A

25. Baseline liver enzyme levels should be obtained in children with NAFLD before starting any medication known to be hepatotoxic. There is insufficient evidence to guide frequency of monitoring for enzyme elevation after initiation of potentially hepatotoxic medications and monitoring should be guided by the baseline severity of the liver disease and the relative potential for hepatotoxicity of the medication. Strength: 1, Evidence: C

26. If potentially hepatotoxic drugs are being considered in patients with NAFLD, a baseline liver biopsy may be reasonable to consider for assessing the severity of liver disease before beginning the medication. Strength: 2, Evidence: C

27. Providers should remain alert to psychosocial issues and screen children with NAFLD for these when indicated. Strength: 1, Evidence: B

ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; CT = computed tomography; HbA1c = glycosylated hemoglobin; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis; T2DM = type 2 diabetes mellitus; WLS = weight loss surgery.

Copyright © ESPGHAL and NASPGHAN. All rights reserved.
surface antibody, 82% had immune protection. The Red Book recommends against routine postimmunization testing for anti-HBs unless the child falls into specific risk groups.

**Recommendations**

23. Children with NAFLD should be vaccinated routinely against hepatitis A. Strength: 1, Evidence: B.

24. Children with NAFLD should have prior receipt of HB vaccine verified and be immunized if no prior vaccination was received. Strength: 1, Evidence: A

**Initiation and Monitoring of Potentially Hepatotoxic Medications**

Children with NAFLD occasionally require medications for other conditions such as diabetes, infections, attention deficit hyperactivity disorder, psychiatric illness, or other chronic illnesses. Certain medications commonly used for these conditions, such as potentially hepatotoxic drugs, require increased frequency of monitoring. A common example is the utilization of metformin for T2DM in patients who have both NAFLD and diabetes. Current recommendations are to evaluate transaminases before starting metformin and to check liver enzymes at the time of diagnosis of T2DM. Evidence is, however, lacking on how often to monitor liver enzymes after initiating therapy. Atypical antipsychotic drugs can also cause rapid and severe weight gain and emergence of cardiometabolic risk factors, and elevated liver enzymes in previously normal weight children. Liver enzymes therefore should be checked before starting atypical antipsychotics and are typically monitored during the course of therapy.

**Recommendations**

25. Baseline liver enzyme levels should be obtained in children with NAFLD before starting any medication known to be hepatotoxic. There is insufficient evidence to guide frequency of monitoring for enzyme elevation after initiation of potentially hepatotoxic medications and monitoring should be guided by the baseline severity of the liver disease and the relative potential for hepatotoxicity of the medication. Strength: 1, Evidence: C.

26. If potentially hepatotoxic drugs are being considered in patients with NAFLD, a baseline liver biopsy may be reasonable to consider for assessing the severity of liver disease before beginning the medication. Strength: 2, Evidence: C.

**Quality of Life**

Because NAFLD is a chronic disease, it has the potential to affect more than just physical health in children. Quality of life is decreased among children with obesity with NAFLD compared to children with obesity without NAFLD (164). Indirect effects such as the emotional toll of worrying about a chronic liver disease may also be a contributor.

**Recommendation**

27. Providers should remain alert to psychosocial issues and screen children with NAFLD for these when indicated. Strength: 1, Evidence: B.

**CONCLUSIONS AND RESEARCH NEEDS**

The emergence of NAFLD has been an important change in the landscape of pediatric liver disease. The recommendations in this guideline are summarized in Table 5. Substantial gaps in knowledge, however, remain and are research priorities. These gaps include the following:

1. Delineating the natural history of pediatric NAFLD and identifying risk factors in childhood that predict progression versus regression and identify those at greater risk of adverse health outcomes.

2. Noninvasive detection of NAFLD and NASH and quantification of steatosis, inflammation, hepatocellular injury, and fibrosis. Longitudinal studies of imaging and biomarkers are needed to better determine their role in clinical care.

3. Well-designed clinical trials to determine optimal treatment approaches, including the role of specific dietary interventions, type and duration of exercise, validation of pilot studies of promising therapies, and identification of novel medications, and role of weight loss surgery.

**REFERENCES**


nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med 2014;189:66–76.
Vos et al


111. Bjelakovic G, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? *PLoS One* 2013;8:e74558.


